SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (355)8/3/2004 11:56:09 AM
From: keokalani'nui  Read Replies (1) | Respond to of 590
 
IMCL major problems with its chemo-combo patent are novelty and non-obviousness.

If you go WAAAY back in IMCL thread I think there will be some discussion.



To: tuck who wrote (355)8/4/2004 10:05:32 AM
From: Icebrg  Respond to of 590
 
>>Someone - Erik>>

I am on the road travelling Germany/Holland and Belgium by bicycle. Sorry, very little time for biotech during August. And it is warm. Take care everyone.

There is an Imclone patent for the use of a mAb in combination with chemo if I remember correctly.

Erik


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News